Bioventures Investors
VC Fund
Wellesley, United States
Bioventures Investors is a VC fund in Wellesley focused on Health Care and Biotechnology. Bioventures Investers is a private equity firm that offers venture capital investment services for firms in the life sciences and healthcare industries. It was founded by Marc Goldberg and is based in Massachusetts.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 5%
Last updated:
For AI agents: llms.txt
Industries Bioventures Investors invests in
Stages Bioventures Investors invests in
Countries Bioventures Investors invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anthony Coia
|
|||
Jeffrey Barnes
|
|||
Jonathan P. Gertler, MD
|
|||
Marc Goldberg
|
|||
Peter Feinstein
|
|||
| See all 6 contacts → | |||
Investment Focus
Industry
- Health Care 11 (58%)
- Biotechnology 10 (53%)
- Medical 6 (32%)
- Genetics 3 (16%)
- Medical Device 3 (16%)
Stage
- Series C 5 (26%)
- Series A 4 (21%)
- Series B 3 (16%)
- Series D 3 (16%)
- Funding Round 3 (16%)
Country
- United States 13 (68%)
- China 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anthony Coia
Principal
|
Principal | Total investments: 0 | Find email | |
|
Jeffrey Barnes
General Partner
|
General Partner | Total investments: 0 | Find email | |
|
Jonathan P. Gertler, MD
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Marc Goldberg
General Partner
|
General Partner | Total investments: 0 | Find email | |
|
Peter Feinstein
General Partner
|
General Partner | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Georgiamune
|
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases. | $75M / Series A / Aug 09, 2023 | |
BRAINBox Solutions
|
BRAINBox provides objective evidence of injury and prediction of patient recovery. BRAINBox Solutions' multi-modality approach is led by the leaders in the industry. It includes blood biomarker panels available on a point of care instrument and standard laboratory systems. | $23M / Series A / Dec 08, 2020 | |
Kanova
|
Kanova is a biopharmaceutical firm. | $16.3M / Series A / Nov 26, 2018 | |
Endotronix
|
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worseningheart failure.It was founded in 2007 and is based in Lisle, Illinois. | $70M / Series D / Sep 14, 2018 | |
|
Endotronix
|
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worseningheart failure.It was founded in 2007 and is based in Lisle, Illinois. | $37.1M / Series C / Jul 05, 2016 | |
Cylene Pharmaceuticals
|
Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatricbrain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California. | $12M / Series D / Sep 24, 2010 | |
Hydrocision
|
HydroCision develops, manufactures, and markets fluidjet based surgical tools for minimally invasive spine surgery requirements. Its products include SpineJet HydroSurgery System that is used to ablate, cut, and remove targeted tissue for spinal procedures, Spinejet, water-based technology solutions for minimally invasive spine surgeryrequirements, SpineJet HydroDiscectomy Systems, which are used to remove tissue without the risk of thermal energy for minimally invasive discectomy procedures, and AlloJet, systems to prepare bone allografts. The company also provides customer care services. HydroCision, Inc. was formerly known as Surgijet Corporation and changed its name to HydroCision, Inc. in November 1996. The company was founded in 1994 and is headquartered in North Billerica, Massachusetts. | Sep 15, 2010 | |
Claros Diagnostics
|
Claros Diagnostics, Inc. is creating products to move in-vitro medical diagnostic tests out of the laboratory and into the hands of physicians and patients. | $4M / Series B / Mar 23, 2009 | |
Hydra Biosciences
|
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that addresssignificant unmet medical needs.Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs.Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures. | $22M / Series D / Jan 16, 2009 | |
|
Hydra Biosciences
|
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that addresssignificant unmet medical needs.Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs.Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures. | $34M / Series C / Mar 13, 2008 | |
| See all 19 investments → | |||
Co-Investors
Lilly Ventures
4 deals together
Advanced Technology Ventures
3 deals together
Oxford Bioscience Partners
3 deals together
SV Health Investors
3 deals together
Abingworth
2 deals together
Accelerated Technologies Partners
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Bioventures Investors invest in?
Bioventures Investors invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Series A stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bioventures Investors?
Public channels for Bioventures Investors include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Bioventures Investors?
The team at Bioventures Investors includes Anthony Coia (Principal), Jeffrey Barnes (General Partner) and Jonathan P. Gertler, MD (Managing Director), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
